The 28 references in paper A. Mudunov M., А. Мудунов М. (2017) “НИВОЛУМАБ В ЛЕЧЕНИИ РЕФРАКТЕРНОГО РЕЦИДИВНОГО И МЕТАСТАТИЧЕСКОГО ПЛОСКОКЛЕТОЧНОГО РАКА ОРГАНОВ ГОЛОВЫ И ШЕИ. РЕЗУЛЬТАТЫ КЛИНИЧЕСКОГО ИССЛЕДОВАНИЯ III ФАЗЫ CHECKMATE 141 // NIVOLUMAB IN THE TREATMENT OF REFRACTORY RECURRENT AND METАSTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA. THE RESULTS OF A PHASE III CLINICAL TRIAL (CHECKMATE 141)” / spz:neicon:ogsh:y:2017:i:3:p:74-86

1
Pignon J.P., le Maître A., Maillard E., Bourhis J.; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol
(check this in PDF content)
2
09;92:4–14. DOI: 10.1016/j. radonc.2009.04.014. PMID: 19446902. 2. Bernier J., Domenge C., Ozsahin M. et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350(19):1945–52. DOI: 10.1056/NEJMoa032641. PMID: 15128894.
(check this in PDF content)
3
Cooper J.S., Pajak T.F., Forastiere A.A. et al. Postoperative concurrent radiotherapy and chemotherapy for highrisk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350(19):1937–44. DOI: 10.1056/ NEJMoa032646. PMID: 15128893.
(check this in PDF content)
4
Saloura V., Cohen E.E., Licitra L. et al. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2014;73:1227–39. DOI: 10.1007/s00280-014-2459-z. PMID: 24714973.
(check this in PDF content)
5
Topalian S.L., Drake C.G., Pardoll D.M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27:450–61. DOI: 10.1016/j.ccell.2015.03.001. PMID: 25858804.
(check this in PDF content)
6
Li J., Jie H.B., Lei Y. et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res 2015;75:508–18. DOI: 10.1158/00085472.CAN-14-1215. PMID: 25480946.
(check this in PDF content)
7
Badoual C., Hans S., Merillon N. et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73:128–38. DOI: 10.1158/0008-5472.CAN-12-2606. PMID: 23135914.
(check this in PDF content)
8
Concha-Benavente F., Srivastava R.M., Trivedi S. et al. Identification of the cellintrinsic and -extrinsic pathways downstream of EGFR and IFNγ that inducePD-L1 expression in head and neck cancer. Cancer Res 2016;76:1031–43. DOI: 10.1158/0008-5472.CAN-15-2001. PMID: 26676749.
(check this in PDF content)
9
Mapara M.Y., Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22:1136–51. DOI: 10.1200/ jco.2004.10.041.
(check this in PDF content)
10
Muenst S., Läubli H., Soysal S.D. et al. The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med 2016; 279(6):541–62. DOI: 10.1111/joim.12470. PMID: 26748421.
(check this in PDF content)
11
Gillison M.L. Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol 2009;21:439–44. DOI: 10.1097/ CCO.0b013e32832f3e1b.
(check this in PDF content)
12
Fuereder T. Immunotherapy for head and neck squamous cell carcinoma. memo (2016) 9:66–69. DOI 10.1007/s12254016-0270-8.
(check this in PDF content)
13
Ferris R.L. Immunology and immunotherapy of head and neck cancer. J Clin Oncol 2015;33:3293–304. DOI: 10.1200/jco.2015.61.1509.
(check this in PDF content)
14
Kuss I., Hathaway B., Ferris R.L., Gooding W., Whiteside T.L. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10:3755–62. DOI: 10.1158/1078–0432.ccr-04-0054.
(check this in PDF content)
15
Nguyen N., Bellile E., Thomas D. et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. HeadNeck 2016;38(7):1074–84. DOI: 10.1002/ hed.24406. PMID: 26879675.
(check this in PDF content)
16
Lalami Y., Awada A. Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. Cancer Treat Rev 2016;43:113–23. DOI: 10.1016/j.ctrv.2016.01.001.
(check this in PDF content)
17
Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9. DOI: 10.1038/ nature10673. PMID: 26827699.
(check this in PDF content)
18
Zandberg D.P., Strome S.E. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 2014;50:627–32. DOI: 10.1016/j. oraloncology.2014.04.003. PMID: 24819861.
(check this in PDF content)
19
Parikh F., Duluc D., Imai N. et al. Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPVrelated oropharyn-gealcancer. Cancer Res
(check this in PDF content)
20
4; 74(24):7205–16. DOI: 10.1158/0008-5472.can-14-1913. 20. Swanson M.S., Sinha UK. Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer – Review of current data. Oral Oncology 2015; 51:12–15. DOI: 10.1016/j.oraloncology.2014.10.010. PMID: 25459157.
(check this in PDF content)
21
Alexandrov L.B., Nik-Zainal S., Wedge D.C. et al. Signatures of mutational processes in human cancer. Nature 2013;500:415–21. DOI: 10.1038. nature12477. PMID: 23945592.
(check this in PDF content)
22
Ferris R.L., Blumenschein G.Jr, Fayette J. et al. Nivolumab for Recurrent SquamousCell Carcinoma of the Head and Neck. N Engl J Med 2016;375(19):1856–67. DOI: 10.1056/NEJMoa1602252. PMID: 27718784.
(check this in PDF content)
23
Haddad R. et al. Treatment beyond progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in the Phase 3 Checkmate 141 Study. Poster presented at the American Association for Cancer Research Annual Meeting; April 1–5, 2017; Washington, DC, USA.
(check this in PDF content)
24
Gillison M.L. et al. Presented at ASCO 2017, abstract 6019.
(check this in PDF content)
25
Srivastava R.M., Lee S.C., Andrade Filho P.A. et al. Cetuximab-activated natural killer and dendabstractritic cells collaborate to trigger tumor antigenspecific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013;19:1858–72.
(check this in PDF content)
26
Concha-Benavente F., Srivastava R.M., Trivedi S. et al. Identification of the CellIntrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res 2016;76(5):1031–43.
(check this in PDF content)
27
Ferris R.L. et al. Presented at ASCO 2017, abstract 6020.
(check this in PDF content)
28
Concha-Benavente F. et al. Presented at ASCO 2017, abstract 6050. Статья поступила: 29.09.2017. Принята в печать: 23.10.2017. Article received: 29.09.2017. Accepted for publication: 23.10.2017.
(check this in PDF content)